Long-term Monitoring of Female Acute Uncomplicated Cystitis Cases after Lomefloxacin Single-dose Therapy

DOI Web Site 12 References

Bibliographic Information

Other Title
  • 女子急性単純性膀胱炎の単回療法後の長期観察
  • 女子急性単純性膀胱炎の単回療法後の長期観察--Lomefloxacin100mgと300mgによる検討
  • ジョシ キュウセイ タンジュンセイ ボウコウエン ノ タンカイ リョウホウゴ
  • Lomefloxacin 100mgと300mgによる検討

Search this article

Abstract

Female acute uncomplicated cystitis responds relatively well to antimicrobial chemotherapy, but this is also a disease which shows a high frequency of recurrence. However, there have been no published reports regarding long-term monitoring of the course of this disease after therapy has been administered. Accordingly, using primarily a questionnaire, the authors carried out long-term monitoring (for a mean of 242 days) of the natural course of cases of female acute uncomplicated cystitis after single-dose therapy with lomefloxacin (LFLX), a new quinolone antimicrobial agent. The subjects of this study were female patients diagnosed as having acute uncomplicated cystitis with pain upon urination, pyuria ( & ge;10 WBCs/hpf) and bacteriuria ( & ge;104cfu/ml). LFLX was orally administered as a single dose of 100 mg or 300 mg, and the therapeutic efficacy was evaluated on the 3rd and 7th days thereafter. In principle, the evaluation of cure was performed on the 7th day after LFLX administration, and monitoring was conducted to detect early recurrence during the next 7 days (i.e., through the 14th day after treatment). Then the subjects were monitored for late recurrence during a mean follow-up period of 242 days by means of a questionnaire. Confirmation of recurrence was carried out to the greatest extent possible.<BR>It was possible to carry out long-term monitoring of the natural course of 101 cases of female acute uncomplicated cystitis in which the clinical efficacy on the 3rd day after LFLX treatment had been evaluated as good or excellent. Analysis of the pattern of change in the recurrence rate by application of the Kaplan-Meier method revealed that, for patients monitored for 270 days or more, the recurrence rate was 23.4% for 47 cases in the LFLX 100-mg group and 11.1% for 54 cases in the LFLX 300-mg group. The overall recurrence rate was 16.8%. These data indicate that recurrence was less likely to occur in the LFLX 300-mg group, but the difference between the two dosage groups was not statistically significant. According, it was surmised that recurrence is the natural course in approximately 17% of cases of female acute uncomplicated cystitis during the roughly nine-months period after single-dose antimicrobial therapy.

Journal

  • Kansenshogaku Zasshi

    Kansenshogaku Zasshi 69 (1), 45-53, 1995

    The Japanese Association for Infectious Diseases

References(12)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top